This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid…

Refractory Differentiated Thyroid Gland Carcinoma

~Estimated

~$10 – $7,500

ECOG-ACRIN Cancer Research GroupNCT06475989

Phase 2

A Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment wi…

Locally Advanced Differentiated Thyroid Gland CarcinomaLocally Advanced Poorly Differentiated Thyroid Gland CarcinomaLocally Advanced Thyroid Gland Follicular Carcinoma+18 more

Estimated

~$10 – $7,500

Jochen LorchNCT06959641